MeCP2 AND DNA METHYLATION: IN LIMINE
====================================

In 2012, the twentieth anniversary of MeCP2 protein identification will be celebrated ([@B41]). The impulse that this discovery gave to research in various, often apparently unrelated biological fields, from gene regulation to medical genetics, has been immense. Here we cannot describe the enormous weight of data produced, in 20 years, by an increasing number of teams. Rather, we wish to review current research on the MeCP2 biology starting from older scientific hypotheses.

MeCP2 was the second methyl-CpG-binding protein to be identified, although it was the first to be cloned. In fact, [@B8] demonstrated that the methyl-CpG-binding protein MeCP1 can mediate the repression of transcription from densely methylated genes. MeCP1 is able to bind various methylated sequences "*in vitro*," if at least 12 symmetrically methylated CpGs are available. Like many important findings, MeCP2 was discovered "by accident" by [@B8], who were attempting to identify the factors that bind unmethylated DNA to protect CpG islands from DNA methylation ([@B16]). Rat MeCP2 had been successfully isolated through its ability to bind methylated substrates. Then, after its purification, its cDNA had been cloned, thus enabling the knowledge of the nucleotide sequence of the first methyl CpG DNA gene ([@B41]).

MeCP2 is able to bind at a genome-wide level, with the need of a single, methylated CpG. This weak discrimination is in agreement with its diffuse nuclear signal in rat cells. In mouse cells, given their peculiar heterochromatin organization, the staining is extremely evident in the pericentromeric heterochromatin, closely resembling the distribution of major satellite DNA ([@B41]). Mouse satellite DNA is enriched of methylated CpGs, thus explaining the co-localization of MeCP2 with these genomic regions. MeCP2 was the first methyl-binding protein to be biochemically dissected, revealing the presence of a number of functional domains. The most noticeable domains are the methyl-binding domain ([@B54]), responsible for binding with the methylated cytosines and the transcriptional repression domain ([@B52]), which mediates the link with the histone modifications ([@B34]; [@B55]; [@B21]) and the co-repressors. They play a fundamental role in modulating the functions of MeCP2, the main one being, without doubt, the transduction of DNA methylation. These functions fit with an earlier study reporting that the loss of the X-linked methyl-CpG-binding protein 2 (MeCP2) caused embryonic lethality in chimeric mice ([@B64]). Taken together, these data highlighted the role(s) of MeCP2 as a genome modulator, whose functions are indispensable for life.

DNA methylation is present, in various degrees, from bacteria to invertebrates and vertebrates. It plays a role in defending bacterial genomes from foreign DNA invasion ([@B31]). Vertebrate genomes are globally methylated, whereas in invertebrate genomes DNA methylation is patchy. DNA methylation is involved in chromatin remodeling in vertebrates, whereas it is often located inside the genes in invertebrates, such as in *D. melanogaster* ([@B47]). Its genome-wide pattern, in vertebrates, prompted Bird to hypothesize an association between a global repressive effect of DNA methylation and the increase in gene number, which is evident when switching from invertebrate to vertebrate genomes ([@B6]). In fact, a major change in the distribution of DNA methylation occurred at the invertebrate--vertebrate boundary ([@B65]; [@B31]). Following Bird's hypothesis, the global repressive effects of DNA methylation may act as an additional mechanism to suppress transcriptional noise together with the acquisition of a nuclear envelope and the arrangement of the chromatin, which mark the prokaryotes/eukaryotes boundary. This is clearly postulated: "*global improvements in the ability to suppress noise will permit an increase in the maximum gene number, allowing more genes to be tolerated*" ([@B6]).

[@B31] added further substance to this hypothesis suggesting that "*to increase the fidelity of DNA methylation-mediated silencing, and to protect against extensive mutation, there was also a coordinate increase in the number and diversity of methyl CpG binding proteins encoded in the proto-vertebrate genome*". Hendrich and Bird identified a family of methyl-binding protein genes, characterized, similarly to MECP2, by the presence of the methyl-DNA binding domain (MBD). These proteins, called MBD1, MBD2, MBD3, and MBD4 ([@B30]) were all (except for MBD3) characterized by their ability to bind methylated DNA. Only MBD2 and MBD3 were conserved in invertebrates: the ancestral MBD2/3 gene was encoded by a single gene in invertebrate genomes, in contrast to the two separate genes encoded by vertebrates ([@B31]).

Thus, if a global DNA methylation has been used, by vertebrate genomes, to reduce unscheduled transcription, thereby increasing the gene number, this would similarly provide an evolutionary pressure to increase the number and diversity of the protein(s) capable of repressing transcription through the binding of methylated DNA.

MECP2 AND RETT SYNDROME
=======================

Rett syndrome (RTT) is a sporadic post-natal progressive neurodevelopmental disorder occurring with a frequency of 1/10000--15000 live females births and is considered the second most common cause of mental retardation in females ([@B58]; [@B27]). The large majority of cases (99%) are sporadic. In 1999, Zoghbi and colleagues ([@B3]) were able to associate loss-of-function heterozygous mutations in the MECP2 gene to classical RTT patients. The discovery of the MECP2 mutations underlying RTT was a surprise because the large amount of data, summarized above, makes the association of MECP2 to a monogenic disease astonishing.

Besides the large number of studies on patients, the modeling of RTT in mice has been instrumental in order to elucidate the molecular basis of the disease. Mouse models have also been pivotal in the study of expression profiling alterations, necessary to identify putative MeCP2 target genes. They have helped in the elucidation of many questions of biomedical importance: is RTT a pure neuronal disease? Is MECP2 dosage important for the establishment of a pathogenic status? Is RTT reversible?

Two Mecp2 null mice obtained with Cre-LoxP technology and carrying an ubiquitous deletion, were viable but affected by severe neurological symptoms characteristic of RTT ([@B14]; [@B26]). The comparative analysis of knock out and brain selective deletions of Mecp2 suggested that the function of this gene is relevant for the central nervous system ([@B14]; [@B26]). Moreover, the deletion of MeCP2 in selected brain regions or neuronal sub-types revealed the presence of specific subsets of null phenotypes, allowing to ascribe to MeCP2 different neuronal-specific functions ([@B22]; [@B60]; [@B13]).

MeCP2 dosage matters: a mouse over-expressing a transgene containing the human MECP2 locus that shows a near twofold MeCP2 expression, showed severe progressive neurological phenotypes ([@B18]). The effect of MECP2 over-expression has also been observed in humans, where a double dosage of MECP2 causes a severe developmental delay and mental retardation ([@B42]). Such evidence suggests that MeCP2 levels must be fine regulated *in vivo* and even a mild over-expression of this gene can have a dramatic effect.

The concept of RTT as a pure neuronal disease has recently been challenged with results implicating the involvement of the glial cells in the pathogenesis of RTT ([@B4]; [@B46]; [@B67]). More recently, it has been suggested that the microglia may influence the onset and progression of RTT by releasing elevated doses of glutamate, exerting a toxic effect on neurons in a non-cell autonomous fashion ([@B45]). Very interestingly, null phenotypes in mouse models can be reversed by the re-insertion of the Mecp2 gene ([@B18]; [@B43]; [@B35]), while its over-expression by twofold is deleterious ([@B18]; [@B43]). An almost complete reversibility of the null phenotypes was obtained after the onset of the symptoms, by removing a stop cassette in the Mecp2 gene by a Cre-mediated excision induced by tamoxifen administration ([@B25]). These data suggest that the neurological defects caused by Mecp2 mutations can potentially be reversed.

MeCP2 AND TRANSCRIPTIONAL CONTROL
---------------------------------

The apparent dichotomy of MeCP2 functions (genome-wide vs gene-specific regulator) has been widely debated. Transcriptional profiling studies comparing the total brains of RTT patients or mouse models with controls have revealed only subtle differences in gene expression dampening a role for MeCP2 as a global regulator of transcription ([@B10]). A number of reports highlighted BDNF as a bona fide target of MeCP2 in rodent systems ([@B15]; [@B48]). BDNF is a key signaling molecule involved in brain development and plasticity ([@B23]; [@B17]). The mechanism of its transcriptional regulation is, therefore, quite controversial ([@B20]; [@B12]).

To simplify the expression analysis of a complex tissue such as the brain, Zoghbi and colleagues ([@B11]; [@B5]) performed microarray expression analyses, respectively, in the hypothalamus and cerebellum of Mecp2 null mice and of over-expressing mice (MECP2-Tg; [@B18]), comparing the results with wild type (WT) mice. Surprisingly, both reports revealed that MeCp2 is responsible for a subtle repression but also for an activation of many genes, and that some of them were similarly, deregulated in both hypothalamus and cerebellum of the Mecp2 null and MECP2-Tg mice (**Figures [1A](#F1){ref-type="fig"},[B](#F1){ref-type="fig"}**). Furthermore, it has been confirmed that MeCP2 directly binds the promoter region of the genes down-regulated in the Mecp2 null mice and up-regulated in the MECP2-Tg mice, while sequential ChIP assays have revealed that the promoter of the activated genes is simultaneously associated with both MeCP2 and the known transcriptional activator CREB1 (**Figure [1B](#F1){ref-type="fig"}**). These data suggest that MeCP2 regulates the expression of a wide range of genes in different brain sub-regions and point to a role for MeCP2 as a modulator of transcription that can both activate or repress target genes ([@B11]; [@B5]). Moreover, the transcriptional alterations observed in the MECP2-Tg mice have confirmed the deleterious effect of the Mecp2 over-expression reported by different research groups ([@B18]; [@B43]).

![**(A)** An example of MeCP2 mediated transcriptional repression: the methyl-DNA binding domain (MBD) binds methylated CpG sites and recruits histone deacetylases and co-repressors (Sin3A), inducing chromatin compaction and gene silencing ([@B55]; [@B15]; [@B38]). **(B)** MeCP2 is able to activate the transcription of some genes in hypothalamus, by binding unmethylated promoters and recruiting CREB1 and, potentially, co-activators ([@B11]). **(C)** MeCP2 is responsible for the silencing of Dlx5/6 imprinted locus by inducing the formation of a silent higher order chromatin loop ([@B32]).](fgene-03-00181-g001){#F1}

A category of genes investigated as a putative target of MeCP2 is that of imprinted genes, whose expression is regulated by differential methylation. For example, several studies have focused on Ube3A, a gene imprinted in the brain ([@B59]) and associated with Prader--Willi and Angelman syndromes. However, to date, the expression alteration of this gene in Mecp2-null mice has not been clearly understood ([@B24]). Another imprinted region bound by MeCP2 in the mouse brain includes the Dlx5 and Dlx6 genes, located in an imprinted gene cluster on chromosome 6. Its transcription is nearly two times greater in brains of Mecp2-null mice compared to those of WT mice and, in the same model, the chromatin loop in the Dlx5/6 locus enriched with methylated H3K9 present in the WT brain is absent (**Figure [1C](#F1){ref-type="fig"}**; [@B32]).

MeCP2 deficiency affects also Line-1 (L1) transcription and retrotransposition: these are, in fact, increased in the mouse brains from null mice and in the neural precursor cells obtained from iPSC and postmortem brains from RTT patients ([@B51]).

The L1 elements are retrotransposons representing 20% of mammalian genomes that may induce genomic alterations, such as insertions and deletions ([@B36]; [@B57]; [@B28]). Moreover, a massive somatic L1 insertion can occur in adult brain tissues, a phenomenon that can alter the expression of the neuronal genes ([@B50]; [@B19]). These data were confirmed by another report which revealed an increased transcript level of the L1-elements, intracisternal A particles, and tandem repetitive units of the mouse major satellite in the Mecp2 null brains compared to WT mice ([@B63]).

MeCP2 AND ITS COFACTORS
-----------------------

As already described regarding the interaction between MeCP2 and CREB, proteins with which it interacts may modify the roles of MeCP2 (**Figures [1A](#F1){ref-type="fig"},[B](#F1){ref-type="fig"}**).

The first potential connection between MeCP2 and chromatin came from the finding that MeCP2 copurifies with the Sin3-histone deacetylase complex ([@B34]; [@B55]). Based on this observation, most current models depict MeCP2 as a transcriptional repressor that facilitates repression through local histone deacetylation mediated by the passive recruitment of histone deacetylases ([@B7]). [@B39] demonstrated that MeCP2 is a non-obligatory component of the Sin3a co-repressor complex. Moreover, MeCP2 exists as a monomeric protein in solution and does not stably associate with other proteins.

In addition to Sin3a, several other factors have been reported to bind mammalian MeCP2, including DNMT1, CoREST, Suv39H1, and c-SKI ([@B55]; [@B40]; [@B44]; [@B37]) although the contribution of these factors to MeCP2-mediated repression is not known.

MeCP2 also interacts with ATRX, a SWI/SNF family ATPase. MeCP2 recruits ATRX to the heterochromatic foci, but this localization is disrupted in Mecp2 null neurons. ATRX localization is disrupted also by the A140V MECP2 mutation found in XLMR patients ([@B56]; [@B53]). Unexpectedly, the complex MeCP2/ATRX with cohesin preferentially binds the unmethylated allele of the H19 gene. This may depend on the association of MeCP2 with this large complex or on regions of non-specific affinity present in MeCP2 ([@B24]).

A binding of MeCP2 to the trithorax-related protein Brahma (Brm) has also been reported. Brm and MeCP2 assemble on the methylated genes involved in cancer and on the FMR1 gene in fragile X syndrome ([@B29]). Therefore, this interaction is still controversial ([@B33]).

A physical interaction between the heterochromatin protein 1 (HP1) and MeCP2 has been demonstrated during the myogenic differentiation. In particular, this interaction leads to the re-localization of HP1γ to the heterochromatin, which correlates with the presence of MeCP2 ([@B2]). There is no doubt that works aimed at the dissection of the interactions of MeCP2 with other partners, in particular using the novel sequencing-based techniques ([@B63]), may open the way to a better understanding of the roles and functions of MeCP2.

MeCP2: GLOBAL REGULATORY ROLES
------------------------------

DNA methylation affects the nuclear architecture, as measured by the gene position alterations in the chromosome territories ([@B49]). A direct role of MeCP2 in nuclear architecture rearrangements has not been reported. Rather, the role(s) of MeCP2 in genome-wide phenomena, such as pericentromeric heterochromatin clustering, has recently been analyzed ([@B9]; [@B1]; [@B62]). During the myogenic differentiation of mouse C2C12 cells, the pericentric heterochromatin domains undergo a reorganization and cluster into a smaller number of larger chromocenters (**Figure [2](#F2){ref-type="fig"}**). These events are accompanied by an increase in the methylation of major satellite DNA and the accumulation of MeCP2 and MBD2 proteins in the nuclei of terminally differentiated muscle cells. Interestingly, the over-expression of MeCP2 and MBD2 in C2C12 myoblasts in the absence of differentiation also induces an aggregation of the chromocenters, indicating that these proteins may be directly involved in the reorganization of heterochromatin architecture. Moreover, studies in Mecp2 null mouse neurons have revealed significant differences in the number and size of the nucleoli and chromocenters compared to WT animals ([@B62]). Already in 2002, it was shown that mice carrying a Mecp2 truncating mutation have a higher level of hyperacetylated histone H3 compared with WT mice, emphasizing a generally altered chromatin architecture ([@B61]). The development of techniques permitting genome-wide epigenomic studies are contributing to the assessment of MeCP2 functions in the chromatin architecture and genome organization.

![**Clustering of pericentromeric heterochromatin domains (chromocenters, blue spots) during myogenic differentiation of C2C12 myoblasts to myotubes ([@B9])**.](fgene-03-00181-g002){#F2}

In 2007, LaSalle and colleagues reported, by ChIP-chip analysis on a neuroblastoma cell line, that more than half of the MeCP2 binding sites are intergenic and that only a small number of them reside in the CpG islands. Moreover, among binding sites located in the CpG islands, many of them are associated with actively transcribed genes, supporting the view of a more complex function of MeCP2 ([@B66]).

Different approaches, reagents, and technologies led, some years later, to the re-establishment of MECP2 as a protein with a global regulatory role ([@B63]). The utilization of next generation sequencing approaches in the neuronal nuclei from the mature mouse brain has revealed that the abundance of MeCP2 is similar to the number of nucleosomes ([@B63]). Moreover, as previously reported ([@B61]), in the absence of Mecp2, the H3 acetylation levels are increased, while the H1 levels are doubled, pointing a role for MeCP2 in the global chromatin organization.

Furthermore, an analysis of binding sites around known regulated genes, such as BDNF and Dlx5/6, transcriptionally active in this cellular system, has revealed a MeCP2 binding across the entire locus, except for the CpG island regions, suggesting that these active promoters are unable to bind MeCP2 due to its hypomethylation state. Moreover, high-throughput data suggest that the MeCP2 binding *in vivo* tracks the density of methyl-CpG in the genome ([@B63]). These latter data have revealed that MeCP2 is one of the most abundant nuclear proteins in the mature neurons suggesting a crucial role for MeCP2 in neurons as a regulator of the entire genome.

The described data suggest that, in addition to the role of MeCP2 as a gene-specific transcriptional regulator, mediated by the association with specific cofactors, the global chromatin-binding function of MeCP2 is crucial for global chromatin dynamics especially during brain maturation. MeCP2 may thus be seen as a multifunctional and structural organizing factor. Furthermore, the interaction of MeCP2 with most regions of the genome, such as the intergenic DNA and repetitive elements, should contribute to keep the rate of somatic mutation and transcriptional noise in the brain low and allows to hypothesize further pathogenic roles for MeCP2 in RTT. This evidence recalls the concept we previously described, focusing on the role of MeCP2 as a key player in genome architecture and regulation.
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